Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan

Annals of Hematology

Volumn 86, Issue 4, 2007, Pages 277-282

  Vela Ojeda, J ^a   Garcia Ruiz Esparza M A ^a   Padilla Gonzalez Y ^a   Gomez Almaguer D ^b   Gutierrez Aguirre C H ^b   Gomez Rangel D ^c   Morales Toquero, A ^c   Ruiz Delgado, G J ^c   Delgado Lamas, J L ^a   Ruiz Arguelles G J ^c  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

Multiple myeloma; Oral and I.V. melphalan; Stem cell autotransplants

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BORTEZOMIB; CARMUSTINE; CD34 ANTIGEN; CIPROFLOXACIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; M PROTEIN; MELPHALAN; ONDANSETRON; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; APHERESIS; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER REGRESSION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; ERYTHROCYTE COUNT; GRAFT REJECTION; HERPES ZOSTER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYCOSIS; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARMUSTINE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELPHALAN; MEXICO; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33847620232     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0235-9     Document Type: Article

References (22)

1. Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE (1996) High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: A dose-toxicity study. Bone Marrow Transplant 17:335-340
2. Alegre A, Lamana M, Arranz R, Fernandez-Villalta MJ, Tomas JF, Figuera A et al (1995) Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 91:380-386
3. Attal M, Harousseau JL, Stoppa AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97
4. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J et al (1998) Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 21:1101-1107
5. Bergsagel DE (1989) Melphalan/prednisone vs drug combinations for plasma cell myeloma. Eur J Haematol 43(Suppl 51):117-123
6. Boccadoro M, Marmont F, Tribalto M (1991) VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone in the treatment of multiple myeloma even in high risk patients. J Clin Oncol 9:444-448
7. Bosanquet AG, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355-362
8. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883
9. Fassas A, Shaughnessy J, Barlogie B (2005) Cure of myeloma: Hype or reality? Bone Marrow Transplant 35:215-224
10. Gibson J, Ho PJ, Joshua D (2004) Evolving transplant options for multiple myeloma: Autologous and nonmyeloablative allogeneic transplantation. Transplant Proc 8:2501-2503
11. Vela-Ojeda J, Sanchez-Cortes E, Ayala-Sanchez M, Garcia-Chavez J, Garcí-Ruiz Esparza MA, Tripp-Villanueva F et al (1998) Treatment of relapse and refractory multiple myeloma (MM) with intermediate doses of oral melphalan, dexamethasone and GM-CSF (M-80) versus VAD chemotherapy. Blood 92(10) Suppl 1, 284b, abstract # 4225
12. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD (1988) Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 71:723-727
13. Lahuerta JJ, Grande C, Blade J (2002) Myeloablative treatments for multiple myeloma: Update of comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leuk Lymph 43:67-74
14. 2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 99:731-735
15. Reece PA, Kostasek D, Morris RG (1986) The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 49:1318-1321
16. Ruiz-Argüelles A (1992) Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 50:735-743
17. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L (2004) Multiple myeloma in México: A single institution, twenty-year experience. Arch Med Res 35:163-167
18. Samuels BL, Bitran JD (1995) High-dose intravenous melphalan: A review. J Clin Oncol 13:1786-1799
19. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD (1988) The systemic administration of intravenous melphalan. J Clin Oncol 6:1768-1782
20. Tricot G, Alberts DS, Johnson C (1996) Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 2:947-952
21. Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chavez J, Tripp-Villanueva F et al (2002) Intermediate doses of melphalan and dexamethasone are better than VAD chemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 81:262-267
22. Wildiers H, Highley S, De Bruijn EA, Van Oosterom AT (2003) Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42:1213-1242